Literature DB >> 15948726

Pelvic recurrence in stage I seminoma: a new phenomenon that questions modern protocols for radiotherapy and follow-up.

Richard E Power1, John Kennedy, John Crown, Ian Fraser, John A Thornhill.   

Abstract

OBJECTIVE: To highlight the increased risk for pelvic relapse in patients with stage 1 seminoma treated with adjuvant radiotherapy limited to para-aortic template alone. PATIENTS AND METHODS: Over a four-year period, three patients presented with early pelvic recurrence after radical orchidectomy and adjuvant irradiation for stage 1 seminoma. In each case, radiotherapy had been limited to the para-aortic region with omission of the ipsilateral hemi pelvis.
RESULTS: Pelvic recurrences occurred on the ipsilateral tumor side. Durable complete remission was achieved in each case; however, treatment was complex and there was associated morbidity.
CONCLUSION: This significant incidence of pelvic recurrence questions the validity of modern radiotherapy protocol which excludes the ipsilateral pelvis from the radiation field.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948726     DOI: 10.1111/j.1442-2042.2005.01114.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  3 in total

1.  Stage I seminoma: treatment outcome at King Hussein Cancer Center in Jordan.

Authors:  Jamal Khader; Ahmed Salem; Yazan Abuodeh; Abdelateif Almousa; Naim Farah; Fadwa Abdelrahman
Journal:  BMC Urol       Date:  2012-04-24       Impact factor: 2.264

Review 2.  Pure seminoma: a review and update.

Authors:  Noureddine Boujelbene; Adrien Cosinschi; Nadia Boujelbene; Kaouthar Khanfir; Shushila Bhagwati; Eveleyn Herrmann; Rene-Olivier Mirimanoff; Mahmut Ozsahin; Abderrahim Zouhair
Journal:  Radiat Oncol       Date:  2011-08-08       Impact factor: 3.481

3.  Late recurrence of Seminoma in the pelvis: A case report.

Authors:  Seth Swinney; Allen Medway; Luis Brandi; Pranav Sharma
Journal:  Urol Case Rep       Date:  2021-06-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.